Aprea Therapeutics, Inc. (NASDAQ:APRE - Get Free Report) Director Marc Duey sold 6,462 shares of the firm's stock in a transaction dated Friday, October 18th. The shares were sold at an average price of $4.58, for a total value of $29,595.96. Following the completion of the sale, the director now directly owns 233,651 shares in the company, valued at approximately $1,070,121.58. The trade was a 0.00 % decrease in their position. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available at this hyperlink.
Marc Duey also recently made the following trade(s):
- On Wednesday, October 16th, Marc Duey acquired 30,000 shares of Aprea Therapeutics stock. The stock was acquired at an average price of $4.39 per share, for a total transaction of $131,700.00.
- On Monday, October 14th, Marc Duey acquired 190 shares of Aprea Therapeutics stock. The stock was acquired at an average price of $2.58 per share, for a total transaction of $490.20.
Aprea Therapeutics Stock Up 4.6 %
NASDAQ:APRE opened at $4.08 on Friday. Aprea Therapeutics, Inc. has a 52 week low of $2.15 and a 52 week high of $8.85. The company's 50 day moving average price is $3.27 and its 200-day moving average price is $4.10. The stock has a market cap of $22.15 million, a price-to-earnings ratio of -1.23 and a beta of 1.03.
Missed Nvidia? Watch this ASAP
From Brownstone Research | Ad
This little-known project that Bill Gates has been quietly working on that’s about to unleash an AI breakthrough so advanced, it’s going to make ChatGPT look like VHS.
But what’s even more unbelievable?
I believe it’ll make Nvidia’s meteoric rise look like a backyard bottle rocket.
Click here and I’ll tell you everything you need to know.
Aprea Therapeutics (NASDAQ:APRE - Get Free Report) last issued its quarterly earnings results on Monday, August 12th. The company reported ($0.58) earnings per share for the quarter, topping the consensus estimate of ($0.63) by $0.05. The business had revenue of $0.56 million for the quarter, compared to analysts' expectations of $0.10 million. Aprea Therapeutics had a negative net margin of 1,012.37% and a negative return on equity of 56.38%. As a group, sell-side analysts anticipate that Aprea Therapeutics, Inc. will post -2.74 earnings per share for the current year.
Institutional Trading of Aprea Therapeutics
An institutional investor recently bought a new position in Aprea Therapeutics stock. Dimensional Fund Advisors LP purchased a new position in shares of Aprea Therapeutics, Inc. (NASDAQ:APRE - Free Report) in the second quarter, according to its most recent disclosure with the Securities and Exchange Commission. The fund purchased 11,071 shares of the company's stock, valued at approximately $45,000. Dimensional Fund Advisors LP owned 0.20% of Aprea Therapeutics at the end of the most recent quarter. 34.19% of the stock is owned by institutional investors and hedge funds.
Analyst Upgrades and Downgrades
Several research firms recently weighed in on APRE. HC Wainwright restated a "buy" rating and set a $20.00 price target on shares of Aprea Therapeutics in a research report on Thursday. Wedbush restated an "outperform" rating and set a $11.00 price target on shares of Aprea Therapeutics in a research report on Tuesday, August 13th.
View Our Latest Stock Report on APRE
Aprea Therapeutics Company Profile
(
Get Free Report)
Aprea Therapeutics, Inc, a clinical-stage biopharmaceutical company, focuses on developing and commercializing novel synthetic lethality-based cancer therapeutics that targets DNA damage response pathways. Its lead product candidate is the ATRN-119 that is in Phase I clinical trials for treating advanced solid tumors.
Read More
This instant news alert was generated by narrative science technology and financial data from InsiderTrades.com in order to provide readers with the fastest and most accurate reporting. This story was reviewed by InsiderTrades.com's editorial team prior to publication. Please send any questions or comments about this story to [email protected].
